Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CHO PharmaROCO:6586 25 Receivables Turnover is 7.19 as of Dec. 2025. GuruFocus rates ROCO:6586 with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 841 Biotechnology companies, CHO Pharma ranks worse than 72.06% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. CHO Pharma's Revenue for the
six
months ended in Dec. 2025 was NT$0.72 Mil. CHO Pharma's average Accounts Receivable for the
six
months ended in Dec. 2025 was NT$0.10 Mil.
Hence, CHO Pharma's Receivables Turnover for the
six
months ended in Dec. 2025 was 7.19.
CHO Pharma (ROCO:6586) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
CHO Pharma Receivables Turnover Related Terms
CHO Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for CHO Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6586 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, CHO Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CHO Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CHO Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where CHO Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHO Pharma (ROCO:6586) has a Receivables Turnover of 7.19 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CHO Pharma and its competitors. According to the industry distribution chart, CHO Pharma ranks #606 out of 841 companies in the Biotechnology industry, placing it in the top 72.1%.
Is CHO Pharma's Receivables Turnover too high?
CHO Pharma's current Receivables Turnover is 7.19. The Biotechnology industry median Receivables Turnover is 5.27. CHO Pharma's value of 7.19 is 36.4% above this industry median. Based on the distribution chart, CHO Pharma ranks #606 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CHO Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does CHO Pharma's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CHO Pharma ranks #606 out of 841 companies for Receivables Turnover. This places CHO Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.27. CHO Pharma's value of 7.19 is 36.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CHO Pharma's current Receivables Turnover of 7.19 is 36.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on CHO Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CHO Pharma's current Receivables Turnover is 7.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CHO Pharma stock overvalued right now?
CHO Pharma (ROCO:6586) has a current Receivables Turnover of 7.19. The current Receivables Turnover is 7.19 and 36.4% above the Biotechnology industry median of 5.27. CHO Pharma's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For CHO Pharma (ROCO:6586), the current Receivables Turnover is 7.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
25GF Score
Get the complete analysis for ROCO:6586
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6586 has been successfully added to your 
